Key takeaways
- The VA has launched the CRAVE trial to evaluate if weekly semaglutide injections can help veterans reduce alcohol consumption.
- No new drug has been FDA-approved to treat alcohol use disorder in nearly 20 years, and current options are widely underutilized.
- Emerging data suggests GLP-1 therapies interact with brain reward pathways to potentially curb cravings and substance use.
The therapeutic potential of GLP-1 medications may soon extend far beyond metabolic health. The U.S. Department of Veterans Affairs (VA) has officially launched a major nationwide clinical trial to evaluate whether semaglutide—the active ingredient in popular medications like Ozempic and Wegovy—can effectively help veterans reduce their alcohol consumption.
As reported by Pulmonology Advisor and HealthDay News, the trial represents a significant step forward in exploring how GLP-1 receptor agonists impact the brain's reward pathways. If successful, the study could pave the way for the first newly approved medication to treat alcohol use disorder (AUD) in nearly two decades.
For Americans currently navigating the landscape of GLP-1 therapies, this trial highlights the rapidly expanding science behind these medications. It also offers a glimpse into how these treatments might be prescribed and covered in the future.
The CRAVE Trial: Testing Semaglutide for Alcohol Use Disorder
The clinical trial, officially named "Cessation or Reduction of Alcohol Consumption in Veterans" (CRAVE), is designed to address a critical gap in addiction treatment. According to VA data, more than 400,000 veterans have been diagnosed with AUD. Nationwide, the disorder is estimated to affect nearly 11% of all U.S. adults.
Despite the prevalence of AUD, treatment options have remained stagnant. The listing on ClinicalTrials.gov notes that no new medication has received approval from the U.S. Food and Drug Administration (FDA) to treat AUD in almost 20 years.
Currently, oral naltrexone is the most widely prescribed medication for alcohol dependence, but researchers note that it works only modestly well. Underuse is also a major hurdle. Even within the VA system—which actively promotes medication as a best clinical practice—only about 40,000 of the 400,000 veterans diagnosed with AUD are receiving drug therapy. Nationwide, fewer than 2% of eligible adults receive medication for the disorder in any given year.
How the Trial is Structured
- Participants: The study aims to enroll more than 600 veterans aged 18 to 80 who have been diagnosed with moderate to severe alcohol use disorder.
- Locations: Recruitment is active across 18 VA medical centers nationwide, ranging from Seattle, Washington, to Orlando, Florida.
- Protocol: Participants will receive weekly injections of either semaglutide or a placebo for approximately 24 weeks, followed by a formal safety follow-up period.
- Key Metrics: Researchers will monitor changes in weekly drinking habits, overall physical health, and self-reported quality of life.
Why Do GLP-1 Drugs Affect Substance Use?
The scientific interest in testing semaglutide for addiction stems from how the drug interacts with the central nervous system. Beyond slowing digestion and regulating blood sugar, GLP-1 receptor agonists are believed to act directly on areas of the brain that regulate reward, cravings, and dopamine release.
This study is backed by promising real-world data. A recent study published in the British Medical Journal (BMJ) found that patients prescribed GLP-1 medications experienced lower overall rates of AUD and other substance use disorders compared to matched control patients who were taking non-GLP-1 diabetes drugs. Furthermore, the VA noted that individuals with pre-existing substance use disorders who were prescribed GLP-1 therapies experienced fewer emergency department visits and hospitalizations.
In a press release, VA Secretary Doug Collins emphasized the significance of the research, stating that the trial aims to "expand the tools available to help Veterans take control of their health and recovery" by exploring emerging applications of GLP-1s.
What This Means for GLP-1 Consumers and Telehealth Patients
While the CRAVE trial is focused specifically on military veterans, its findings could have broader implications for the general public and the telehealth industry.
1. Off-Label Prescribing Potential
Currently, semaglutide is only FDA-approved to treat type 2 diabetes (under brand names like Ozempic) and chronic weight management (under the brand name Wegovy). If you are looking to learn more about how these brand-name versions compare in doses and indications, you can read our guide on Ozempic vs. Wegovy.
While physicians have the legal right to prescribe medications "off-label" for unapproved uses, most online medical weight-loss providers restrict their prescribing to patients who meet specific body mass index (BMI) or metabolic health criteria. If clinical trials confirm that semaglutide effectively curbs alcohol cravings, telehealth providers may eventually expand their services to offer GLP-1 therapies specifically for addiction support.
2. The Rise of Compounded Alternatives
Because brand-name GLP-1 medications remain expensive and frequently in short supply, many patients turn to compounding pharmacies to access their prescriptions. Understanding the differences between compounded vs. brand-name semaglutide is essential for anyone considering this route. If semaglutide is eventually recognized as an effective treatment for behavioral health conditions like AUD, demand for both brand-name and compounded options is likely to rise even further.
3. Insurance Coverage Considerations
Currently, obtaining insurance coverage for GLP-1 medications can be difficult. Many private insurers and employer programs exclude weight-loss medications entirely. To understand what is typically required for approval, you can read our breakdown of what insurance covers for GLP-1s. If semaglutide eventually gains FDA approval for alcohol use disorder, it could open entirely new pathways for insurance coverage under behavioral health benefits, though this process would take years of regulatory review.
Exploring Current GLP-1 Options
For those interested in exploring GLP-1 medications for their currently approved indications—such as weight loss or type 2 diabetes—a variety of virtual care options are available. Navigating these services requires comparing monthly subscription fees, clinical support, and medication costs.
To explore and compare the leading telehealth platforms, you can use our interactive tools to compare online GLP-1 providers or browse our comprehensive list of licensed GLP-1 telehealth providers. For patients looking to minimize out-of-pocket expenses, our analysis of the cheapest telehealth GLP-1 programs can help locate affordable clinical care.
Disclaimer: CompareRx does not provide medical advice. If you or a loved one are struggling with alcohol use disorder, consult a qualified healthcare professional to discuss safe, evidence-based treatment plans.